D. Marin

S. Brett, K. Rezvani, D. Marin, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

D. Marin, J. Goldman, M. Bua, 2005, Cancer.

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

E. Lam, D. Marin, F. Villanova, 2010, Haematologica.

Running title: MSC-mediated protection of CML cells from imatinib

D. Marin, F. Villanova, A. Gomes, 2009 .

leukemia after allogeneic stem cell transplantation Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid

C. Craddock, D. Marin, J. Goldman, 2013 .

chronic myeloid leukemia Factors affecting duration of survival after onset of blastic transformation of

D. Marin, J. Goldman, A. Chase, 2013 .

The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib

J. Melo, D. Marin, J. Goldman, 2009, Haematologica.

Personalized medical treatment strategies for patients with chronic myeloid leukemia

D. Marin, J. Apperley, C. Burton, 2005, Expert review of anticancer therapy.

Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.

C. Craddock, D. Marin, J. Goldman, 2002, Blood.

The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.

D. Marin, J. Goldman, M. Bua, 2002, Haematologica.

Current opinions and controversies in chronic myeloid leukaemia

D. Marin, B. Kishore, 2011, Current opinion in oncology.

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

J. Melo, D. Marin, J. Goldman, 2006, Leukemia.

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

K. Rezvani, D. Marin, J. Goldman, 2008, Blood.

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

D. Marin, T. Holyoake, J. Goldman, 2010, Haematologica.

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.

D. Marin, J. Goldman, D. Milojković, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse

D. Marin, J. Goldman, M. Bua, 2005, Leukemia.

Management decisions in chronic myeloid leukemia.

D. Marin, J. Goldman, 2003, Seminars in hematology.

Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.

D. Marin, J. Goldman, M. Bua, 2003, Haematologica.

Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy

D. Marin, J. Goldman, M. Bua, 2007, Leukemia.

Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons

D. Marin, J. Goldman, S. Marley, 2003, British journal of haematology.

Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide.

K. Rezvani, D. Marin, E. Shpall, 2022, Transplantation and cellular therapy.

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT

D. Slade, D. Marin, J. Goldman, 2013, Bone Marrow Transplantation.

Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes.

P. Thall, D. Marin, E. Shpall, 2022, Transplantation and cellular therapy.

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia

R. Clark, D. Marin, J. Goldman, 2013, British journal of haematology.

Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.

D. Marin, N. Barber, S. Clifford, 2011, Leukemia research.

Influence of mycophenolate mofetil on preservation of kidney function in liver transplant patients.

D. Marin, L. Barrera-Pulido, M. Gómez-Bravo, 2010, Transplantation proceedings.

Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients

K. Rezvani, D. Marin, E. Shpall, 2020, Transplant infectious disease : an official journal of the Transplantation Society.

Mycophenolate Mofetil: A Friend or a Foe with PTCy and Tacrolimus Prophylaxis in HLA-Matched donors?

K. Rezvani, R. Jenq, D. Marin, 2022, Transplantation and cellular therapy.

Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy.

D. Marin, J. Goldman, L. Foroni, 2012, Blood.

IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.

R. Başar, K. Rezvani, D. Marin, 2016, Blood.

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.

M. Andreeff, P. Fox, K. Rezvani, 2015, Blood.

Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease

R. Başar, K. Rezvani, D. Marin, 2018, Front. Immunol..

Better allele-level matching improves transplant-related mortality after double cord blood transplantation

K. Rezvani, D. Marin, S. Parmar, 2015, Haematologica.

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune‐mediated pathogenesis

D. Marin, J. Goldman, D. Milojković, 2008, British journal of haematology.

Dual inhibition of ras and bcr‐abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission

D. Marin, C. Chuah, J. Goldman, 2007, British journal of haematology.

Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials.

D. Marin, J. Pavlů, 2009, Clinical lymphoma & myeloma.

The next questions in chronic myeloid leukaemia and their answers.

D. Marin, J. Goldman, D. Milojković, 2013, Current opinion in hematology.

Management of the New Patient with CML in Chronic Phase

D. Marin, 2013, Current Hematologic Malignancy Reports.

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.

D. Marin, J. Goldman, P. Mehta, 2008, Blood.

Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?

D. Marin, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma

K. Rezvani, D. Marin, S. Parmar, 2016, Leukemia & lymphoma.

Noninvasive mechanical ventilation in a patient with respiratory failure after hematopoietic progenitor transplantation

E. González-Barca, A. Grañena, D. Marin, 1998, Bone Marrow Transplantation.

Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.

D. Marin, S. Parmar, E. Shpall, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

P. Szankasi, D. Marin, B. Druker, 2013, Blood.

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.

D. Marin, J. Goldman, D. Milojković, 2007, Blood.

Duplex quantitative PCR for molecular monitoring of BCR‐ABL1‐associated hematological malignancies

D. Marin, J. Goldman, L. Foroni, 2011, American journal of hematology.

Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.

T. Vulliamy, D. Marin, J. Goldman, 2004, Leukemia research.

Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients

D. Marin, J. Goldman, D. Milojković, 2014 .

Significance of minimal residual disease monitoring by real‐time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes

D. Marin, E. Shpall, K. Patel, 2020, Cancer.

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation

M. Andreeff, D. Marin, E. Shpall, 2017, American journal of hematology.

Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia.

K. Rezvani, D. Marin, E. Shpall, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.

D. Marin, E. Shpall, K. Patel, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia

K. Rezvani, D. Marin, H. Kantarjian, 2015 .

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013, Haematologica.

The BCR-ABLT 315 I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors , in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013 .

Does a rise in the BCR‐ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?

K. Rezvani, D. Marin, J. Goldman, 2009, British journal of haematology.

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

Katy Rezvani, David A Largaespada, Jianliang Dai, 2016, The Journal of clinical investigation.

New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition

W. Vainchenker, D. Marin, J. Goldman, 2008, Leukemia.

Reply to D.L. White et al

D. Marin, J. Goldman, 2012 .

European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation.

D. Marin, J. Goldman, Amr Ibrahim, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.

K. Rezvani, D. Marin, J. Goldman, 2010, Blood.

Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects

K. Rezvani, D. Marin, J. Goldman, 2014, British journal of haematology.

BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluation

D. Marin, J. Goldman, L. Foroni, 2012, American journal of hematology.

Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.

D. Marin, J. Goldman, D. Milojković, 2007, Blood.

need for further investigation into the effects of discontinuing imatinib therapy in those patients who wish to conceive.

K. Rezvani, D. Marin, J. Goldman, 2017 .

without having achieved an optimal response myeloid leukemia who interrupt therapy on account of pregnancy Poor outcome after reintroduction of imatinib in patients with chronic

K. Rezvani, D. Marin, J. Goldman, 2013 .

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.

R. Clark, D. Marin, J. Goldman, 2010, Blood.

Brief report EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

D. Marin, J. Goldman, L. Foroni, 2010 .

Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.

D. Marin, J. Goldman, N. Cross, 2006, Blood.

Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia

D. Marin, H. Kantarjian, E. Jabbour, 2012, American journal of hematology.

Brief report Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

K. Rezvani, D. Marin, J. Goldman, 2011 .

Use of Expanded Allogeneic Third Party BK Virus Specific Cytotoxic T Cells to Target Progressive Multifocal Leukoencephalopathy

K. Rezvani, D. Marin, E. Shpall, 2016 .

IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation.

A. Grañena, S. Sanjosé, S. de Sanjosé, 1998, Haematologica.

KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape

Tamara J Laskowski, R. Başar, K. Rezvani, 2022, Nature Medicine.

Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia.

D. Marin, E. Shpall, R. Kanagal-Shamanna, 2021, Transplantation and cellular therapy.

Fludarabine with Myeloablative Timed-Sequential Busulfan in Older Patients: Results of a Randomized Phase II Clinical Trial

K. Rezvani, D. Marin, S. Parmar, 2019 .

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.

K. Rezvani, D. Marin, S. Parmar, 2018, The Lancet. Haematology.

Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.

K. Rezvani, D. Marin, E. Shpall, 2021, Transplantation and cellular therapy.

Phenotype of blasts in chronic myeloid leukemia in blastic phase-Analysis of bone marrow trephine biopsies and correlation with cytogenetics.

K. Naresh, D. Marin, A. Reid, 2009, Leukemia research.

Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.

D. Marin, E. Jabbour, F. Turturro, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL

D. Marin, T. Kadia, E. Jabbour, 2017, Bone Marrow Transplantation.

Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies

K. Rezvani, D. Marin, E. Shpall, 2022, Frontiers in Immunology.

Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.

D. Marin, J. Goldman, J. Apperley, 2006, Blood.

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

D. Marin, J. Goldman, L. Foroni, 2011 .

EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure.

K. Rezvani, D. Marin, J. Goldman, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study

D. Marin, E. Shpall, B. Andersson, 2022, Haematologica.

Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation

D. Marin, L. Foroni, A. Reid, 2012, Haematologica.

Efficacy of combining dasatinib and intensive chemotherapy for patients with chronic myeloid leukemia in blastic transformation

D. Marin, L. Foroni, A. Reid, 2011 .

Results of a 2‐arm, phase 2 clinical trial using post‐transplantation cyclophosphamide for the prevention of graft‐versus‐host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation

K. Rezvani, D. Marin, E. Shpall, 2016, Cancer.

FISH mapping of Philadelphia negative BCR/ABL1 positive CML

D. Marin, A. Reid, J. Apperley, 2008, Molecular Cytogenetics.

A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS

P. Thall, D. Marin, E. Shpall, 2019, Blood.

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

B. Bain, J. Melo, D. Marin, 2002, The New England journal of medicine.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.

P. Thall, R. Başar, K. Rezvani, 2020, The New England journal of medicine.

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

J. Orange, R. Başar, K. Rezvani, 2018, Leukemia.

Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

D. Marin, J. Goldman, I. Roberts, 2012, Blood.

The first case of acute unilateral pan‐ureteritis caused by BK polyomavirus in an allogeneic stem cell transplant patient

D. Marin, M. Nigo, V.E. Mulanovich, 2016, Transplant infectious disease : an official journal of the Transplantation Society.

Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation

D. Marin, A. Chaidos, H. Auner, 2013, Leukemia & lymphoma.

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

K. Rezvani, D. Marin, E. Shpall, 2013, Blood.

Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system

K. Rezvani, D. Marin, J. Goldman, 2012, British journal of haematology.

Targeting the αv integrin-TGF-β axis improves natural killer cell function against glioblastoma stem cells.

Fang Wang, Dihua Yu, R. Başar, 2021, The Journal of clinical investigation.

Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.

Matthew S. McNeill, Jing Wang, M. Konopleva, 2020, Blood.

Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.

D. Marin, J. Goldman, M. Bua, 2003, Haematologica.

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

D. Marin, J. Goldman, L. Foroni, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia.

D. Marin, J. Goldman, A. Chase, 2002, Blood.

Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD

Jing Wang, M. Konopleva, R. Başar, 2021, Frontiers in Immunology.

Technical aspects and clinical applications of measuring BCR‐ABL1 transcripts number in chronic myeloid leukemia

Letizia Foroni, John Goldman, D. Marin, 2009, American journal of hematology.

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

L. Staudt, A. Rosenwald, T. Greiner, 2012, Blood.

Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment.

J. Melo, D. Marin, S. Kamel‐Reid, 2006 .

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.

K. Rezvani, D. Marin, J. Goldman, 2010, Blood.

Prognostic factors and future direction for chronic myeloid leukemia

D. Marin, A. Rotolo, 2013 .

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

M. Konopleva, Z. Estrov, D. Marin, 2017, JAMA oncology.

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

R. Clark, D. Marin, J. Goldman, 2012, Blood.

CIS checkpoint deletion enhances the fitness of cord blood derived natural killer cells transduced with a chimeric antigen receptor

Matthew S. McNeill, Jing Wang, M. Konopleva, 2020, bioRxiv.

Current status of imatinib as frontline therapy for chronic myeloid leukemia.

D. Marin, 2010, Seminars in hematology.

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

Jaspal Kaeda, D. Marin, J. Goldman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical decisions for chronic myeloid leukemia in the imatinib era.

D. Marin, J. Goldman, J. Apperley, 2003, Seminars in hematology.

Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients

W. Winkelmayer, K. Rezvani, A. Gaber, 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.

R. Larson, D. Marin, H. Kantarjian, 2010 .

intention-to-treat analysis in chronic myeloid leukemia patients Responses to second-line tyrosine kinase inhibitors are durable: an

K. Rezvani, D. Marin, J. Goldman, 2013 .

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Katayoun Rezvani, Letizia Foroni, K. Rezvani, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.

K. Rezvani, D. Marin, E. Shpall, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

K. Rezvani, R. Clark, D. Marin, 2012, Blood.

Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning

D. Marin, E. Shpall, U. Popat, 2017, Cancer.

Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML

D. Marin, F. Dazzi, P. Garland, 2010, Bone Marrow Transplantation.

HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection.

K. Rezvani, D. Marin, E. Shpall, 2022, Transplantation and cellular therapy.

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.

K. Rezvani, D. Marin, H. Kantarjian, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantation.

D. Marin, G. Williams, J. Apperley, 2007, Leukemia research.

Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity.

D. Marin, E. Shpall, B. Andersson, 2020, Blood advances.

Inhibition of the αv integrin-TGF-β axis improves natural killer cell function against glioblastoma stem cells

Dihua Yu, R. Başar, K. Rezvani, 2020, bioRxiv.

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion.

D. Marin, E. Shpall, B. Andersson, 2018, Blood.

Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy

Tamara J Laskowski, R. Başar, K. Rezvani, 2021, Cell Reports.

Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes

D. Marin, E. Shpall, Y. Nieto, 2016 .

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

K. Rezvani, D. Marin, H. Kantarjian, 2019, Biology of Blood and Marrow Transplantation.

Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.

R. Başar, K. Rezvani, D. Marin, 2021, Blood.

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.

K. Rezvani, D. Marin, S. Parmar, 2017, Blood.

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.

D. Marin, K. Young, E. Jabbour, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant

D. Marin, E. Shpall, U. Popat, 2023, JCO oncology practice.

Feasibility and Implementation of a Multimodal Supportive Care Program to Improve Outcomes in Older Patients Undergoing Allogeneic Stem Cell Transplantation.

D. Marin, E. Shpall, U. Popat, 2021, Transplantation and cellular therapy.

Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.

D. Marin, J. Apperley, J. Perz, 2006, Haematologica.

Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation

R. Başar, K. Rezvani, D. Marin, 2018, Front. Immunol..

Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

P. Thall, R. Başar, K. Rezvani, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Third Party BK Virus (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansion for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial

P. Thall, D. Marin, E. Shpall, 2016 .

PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase

R. Clark, D. Marin, L. Foroni, 2015, American journal of hematology.

Stem cell transplantation outcomes in lymphoblastic lymphoma

D. Marin, Y. Nieto, R. Champlin, 2017, Leukemia & lymphoma.

Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial

M. Konopleva, K. Rezvani, D. Marin, 2021, Blood.

Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial

P. Thall, K. Rezvani, D. Marin, 2021, Blood.

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

K. Rezvani, R. Clark, D. Marin, 2013, Blood.

Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL

D. Marin, H. Kantarjian, E. Shpall, 2020 .

Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia.

D. Marin, H. Kantarjian, E. Shpall, 2020, Blood.

Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

P. Thall, K. Rezvani, D. Marin, 2019, Blood.

Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies

K. Rezvani, D. Marin, H. Kantarjian, 2015 .

Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome

D. Marin, E. Shpall, B. Andersson, 2021, Cancer.

Minimal Residual Disease Detected By Multiparameter Flow Cytometry and Complex Karyotype Are the Major Prognostic Factors for Relapse after HCT

K. Rezvani, D. Marin, E. Shpall, 2015 .

Mobilization of Ph chromosome‐negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate‐induced complete cytogenetic remission

J. Byrne, D. Marin, T. Holyoake, 2003, British journal of haematology.

Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant

D. Marin, E. Jabbour, L. Medeiros, 2021, Clinical Cancer Research.

Optimal umbilical cord blood collection, processing and cryopreservation methods for sustained public cord blood banking.

K. Rezvani, D. Marin, E. Shpall, 2021, Cytotherapy.

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.

Katayoun Rezvani, Holger W Auner, K. Rezvani, 2010, Blood.

Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

D. Marin, J. Goldman, L. Foroni, 2009 .

Total CD34+ cells per 10 HPF in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response following imatinib treatment

I. Lampert, D. Marin, K. Elderfield, 2007, Histopathology.

Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival

D. Marin, J. Goldman, L. Foroni, 2008 .

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia

D. Marin, J. Goldman, L. Foroni, 2010, Leukemia.

Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed

J. Byrne, R. Clark, D. Marin, 2011, Haematologica.

The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy

R. Clark, D. Marin, J. Goldman, 2011 .

myeloid leukemia: implications for early intervention strategies Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic

K. Rezvani, D. Marin, J. Goldman, 2013 .

Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?

D. Marin, J. Goldman, L. Foroni, 2012 .

The Use of Dasatinib in Chronic Myeloid Leukemia: Some Practical Considerations

D. Marin, J. Goldman, M. Bua, 2007 .

Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements.

D. Marin, A. Reid, J. Apperley, 2008, Cancer genetics and cytogenetics.

Impact of Donor Age in Haploidentical-PTCy Versus MUD-PTCy HCT in AML patients.

K. Rezvani, D. Marin, E. Shpall, 2023, Transplantation and cellular therapy.

Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS

K. Rezvani, D. Marin, E. Shpall, 2023, American journal of hematology.

Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type

K. Rezvani, D. Marin, E. Shpall, 2023, Blood advances.

KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.

R. Hills, K. Rezvani, D. Marin, 2016, Blood.

Pneumonia caused byMicrococcus species in a neutropenic patient with acute leukemia

A. Salar, A. Grañena, D. Marin, 1997, European Journal of Clinical Microbiology and Infectious Diseases.

Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia

D. Marin, E. Shpall, N. Daver, 2022, Blood.

Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease

K. Rezvani, D. Marin, E. Shpall, 2020 .

Use of mycophenolate mofetil in liver transplantation: Andalusian Liver Registry.

D. Marin, M. L. de la Mata, L. Barrera-Pulido, 2009, Transplantation proceedings.

Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant

D. Marin, E. Shpall, Y. Nieto, 2018, Blood.

Percentage of CD34+ cells in a minimum 500‐cell count in bone marrow trephines of patients with chronic myeloid leukaemia provides the best correlation with aspirate blast count

I. Lampert, D. Marin, K. Elderfield, 2005, British journal of haematology.

Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant

D. Marin, K. Young, E. Jabbour, 2023, Bone Marrow Transplantation.

Role of killer cell immunoglobulin-like receptor (KIR)-ligand interactions to prevent relapse in patients (pts) receiving matched unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML).

R. Başar, K. Rezvani, D. Marin, 2019, Journal of Clinical Oncology.

Myeloablative Timed Sequential Busulfan is Safe and Appears Promising in Older Patients with AML/MDS

D. Marin, S. Parmar, E. Shpall, 2016 .

[Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant].

D. Marin, E. Paz-Artal, J. Morales, 2009, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission,

K. Rezvani, D. Marin, J. Goldman, 2011 .

Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering

Tamara J Laskowski, J. Lohr, R. Başar, 2023, Science advances.

for chronic myeloid leukemia patients on long-term therapy Poor adherence is the main reason for loss of CCyR and imatinib failure

K. Rezvani, D. Marin, L. Foroni, 2013 .

Imatinib use in chronic phase CML in clinical practice: the UNIC study

D. Marin, G. Ossenkoppele, G. Verhoef, 2008 .

Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen

K. Rezvani, D. Marin, E. Shpall, 2019, Blood.

Responses to second-line tyrosine kinase inhibitors are durable : an intention-to-treat analysis in chronic myeloid leukemia patients

K. Rezvani, D. Marin, J. Goldman, 2012 .

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

K. Rezvani, D. Marin, J. Goldman, 2012, Blood.

Imatinib or transplant for chronic myeloid leukaemia?

D. Marin, J. Goldman, E. Kanfer, 2003, The Lancet.

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.

R. Clark, D. Marin, J. Goldman, 2010, Blood.

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.

K. Rezvani, D. Marin, S. Parmar, 2017, Blood.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013, Haematologica.

Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy

D. Marin, J. Goldman, M. Laffan, 2012, Haematologica.

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

R. Clark, D. Marin, J. Goldman, 2011 .

Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia.

K. Rezvani, D. Marin, E. Shpall, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.

R. Başar, K. Rezvani, D. Marin, 2017, Blood.

K. Rezvani, D. Marin, E. Shpall, 2016, Cancer.

Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.

D. Marin, S. Parmar, E. Shpall, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Better allele-level matching improves transplant-related mortality after double cord blood transplantation

K. Rezvani, D. Marin, S. Parmar, 2015, Haematologica.

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host

K. Rezvani, D. Marin, J. Goldman, 2011, Haematologica.